PMA device
PearlMatrix Bone Graft
Cerapedics, Inc. · Filler, Bone Void, Synthetic Peptide (NOX, Class III) · First FDA decision Jun 18, 2025, newest Jun 18, 2025
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "PearlMatrix"
MAUDE reports
0
Brand "PearlMatrix", since 2015
PubMed studies
3
Mentioning "PearlMatrix"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- PearlMatrix Bone GraftBreakthroughPMA
P240001 · Decided Jun 18, 2025 · 533 days after receipt
Device type: Filler, bone void, synthetic peptide (NOX) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PearlMatrix", any status and sponsor, newest update first.
No registered device study names "PearlMatrix".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PearlMatrix", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NOX
178 reports: 7 malfunction, 171 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1165-2026 · Started Dec 29, 2025 · Posted by FDA Jan 23, 2026
Reason given: Incorrect expiration date
Cause as FDA categorized it: Labeling Change Control · Device type: Filler, Bone Void, Synthetic Peptide (NOX)
Published research
The most relevant PubMed records for "PearlMatrix"[tiab]. The summary above synthesizes these.
- P-15 Peptide Enhanced Bone Graft Improves Time to Fusion in Transforaminal Lumbar Interbody Fusion: A Randomized, Controlled, Investigational Device Exemption Study.
Harrop JS, Steinmetz MP, O'Toole JE, et al. · Spine (Phila Pa 1976) · 2026Randomized Controlled Trial, Multicenter Study
- P-15 Peptide Enhanced Bone Graft in Transforaminal Lumbar Interbody Fusion: A Randomized, Controlled, Investigational Device Exemption Study Demonstrating Improved Composite Clinical Success.
Harrop JS, O'Toole JE, Steinmetz MP, et al. · Spine (Phila Pa 1976) · 2026Randomized Controlled Trial, Multicenter Study
- 2026 ISASS Spine Bone Graft Policy Update: Class III Technologies and Contemporary Evidence Maturation.
Lavelle WF, Fourman MS, Miloh RY, et al. · Int J Spine Surg · 2026
Other devices of this type
Also filed under product code NOX.
- Augment® Bone GraftBiomimetic Therapeutics, LLC · PMA 2022
- i-FACTOR® Peptide Enhanced Bone GraftCerapedics, LLC · PMA 2024
- AUGMENT InjectableBiomimetic Therapeutics, LLC · PMA 2019
- PearlMatrix P-15 Peptide Enhanced Bone Graft (PearlMatrix Bone Graft)Cerapedics, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.